Can Sage Therapeutics Press Even Further With Its Depression Trial?
Shares of Sage Therapeutics saw a handy gain on Monday after the company announced a successful mid-stage trial for the treatment of major depressive disorder.
Health and Healthcare
All Health and Healthcare Articles
Newest first · Page 176
Can Zosano Pharma Turn Itself Around With This Late-Stage Migraine Trial Win?
Zosano Pharma saw its shares absolutely skyrocket on Monday after the firm gave an update on its late-stage trial for the treatment of migraines.
How Rosy Is the Outlook for Teva Pharmaceutical?
Teva beat estimates on earnings and revenues for both the quarter and the fiscal year and its outlook for 2017 is better than the consensus estimates.
Americans, Worried About Heart Disease, Don’t Know What Causes It
Americans are worried about dying from heart disease. However, a new study shows that most people don't know what causes it.
Major Biotechs Scare Off Loads of Short Sellers
As we approached Trump’s inauguration, the health care sector in general rallied. Now it’s time to see what the bears have to say about this rally.
Are Short Sellers Doubting Trump by Hiking Bets in Major Pharma?
It has yet to be seen how much headway Trump can actually make with heath care reforms, but so far the reaction has been quite positive.
What Is Driving CVS Revenue Growth?
CVS Health reported mixed fourth-quarter financial results before the markets opened on Thursday.
Is This the Big Turnaround Acorda Needs?
Shares of Acorda Therapeutics saw a hand gain in early trading on Thursday after the company reported results from its late-stage Parkinson’s trial.
What Analysts Are Saying About Gilead Sciences After Earnings
24/7 Wall St. has included some highlights from the Gilead Sciences earnings report, as well as what analysts are saying afterward.
Wednesday’s Biggest Biopharma Movers
Not that many biotech and pharma companies were on the move Wednesday, but a few of the smaller caps made splash, while one giant company posted a massive loss.
Why Gilead Earnings Were Not Up to Snuff
Gilead Sciences Inc. (NASDAQ: GILD) reported its fourth-quarter earnings after the markets closed on Tuesday. The company posted $2.70 in earnings per share (EPS) and $7.3 billion in revenue, compared with the consensus estimates…
Is Teva’s CEO Departure Long Overdue?
Teva Pharmaceutical saw its shares tumble on Tuesday after the company announced a changing of the guard. This CEO departure may have been long overdue.
What to Expect From Gilead Earnings
Gilead Sciences is set to report its fourth-quarter financial results after the markets close on Tuesday.
Why Cannabinoid Developer GW Pharma Looks Better Than Ever to Investors
GW Pharmaceuticals, a developer of therapeutics derived from marijuana, reported a smaller than expected loss in its 2017 first quarter.
Why Neos Therapeutics Shares Are Hitting a New Low
Neos Therapeutics saw its shares sink after the company announced that it had priced its secondary offering of common stock.